Medically Reviewed
This article has been reviewed by Dr. Ajit Jha, MBBS, MD Medicine, IMA Lifetime Member. Content is for informational purposes only and does not constitute medical advice. Always consult your doctor before making health decisions.
For the first time in obesity medicine, doctors have two genuinely different classes of injectable weight loss drugs to choose from. Semaglutide (Ozempic/Wegovy) targets one hormone receptor. Tirzepatide (Mounjaro/Zepbound) targets two. The difference in outcomes is not subtle — and choosing between them requires understanding what the data actually shows.
📋 Key Takeaways
- Tirzepatide produces greater weight loss than semaglutide — approximately 20–22% vs 15% of body weight
- No head-to-head trial has directly compared the two at equivalent doses — current comparisons are cross-trial
- Both drugs have similar side effect profiles; tirzepatide may cause slightly less nausea
- Tirzepatide appears superior for blood sugar control in type 2 diabetes
- Semaglutide has stronger cardiovascular outcome data (SELECT trial); tirzepatide trial ongoing
- Cost in India is similar; availability of tirzepatide is more limited
The Fundamental Mechanism Difference
Understanding the drugs requires understanding what they do to hormones.
Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and acts on the brain to reduce appetite. Semaglutide mimics this hormone but with a much longer half-life — once weekly dosing instead of minutes.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also stimulates insulin release but via a different receptor and pathway. By activating both receptors simultaneously, tirzepatide appears to produce additive — possibly synergistic — metabolic effects. The GIP component also enhances fat metabolism in adipose tissue through a mechanism semaglutide lacks.
Head-to-Head: The Weight Loss Numbers
SURMOUNT-1 vs STEP-1: The Best Available Comparison
No dedicated head-to-head randomised trial of tirzepatide vs semaglutide at equivalent doses exists yet (the SURPASS-CVOT trial vs semaglutide is ongoing for cardiovascular outcomes). The best comparisons come from similar trial designs:
| Metric | Semaglutide 2.4mg (STEP-1) |
Tirzepatide 15mg (SURMOUNT-1) |
|---|---|---|
| Average weight loss | 14.9% | 20.9% |
| Participants losing >20% body weight | 31% | 57% |
| Participants losing >25% body weight | ~10% | 36% |
| Trial duration | 68 weeks | 72 weeks |
| Population | Obese, non-diabetic | Obese, non-diabetic |
The difference is clinically meaningful. For a 90kg person, 14.9% weight loss is 13.4kg. Tirzepatide's 20.9% loss is 18.8kg — 5.4kg more from the same drug class. And the proportion reaching 'transformative' weight loss (over 25%) is three times higher with tirzepatide.
Blood Sugar Control: Diabetes Patients
In people with type 2 diabetes, the comparison is even more striking. The SURPASS-2 trial directly compared tirzepatide to semaglutide 1mg (the standard diabetes dose, not the higher obesity dose) in 1,879 patients. Results at 40 weeks:
- HbA1c reduction: tirzepatide 15mg reduced HbA1c by 2.46% vs semaglutide 1mg's 1.86%
- Weight loss: tirzepatide 15mg produced 12.4% body weight loss vs semaglutide 1mg's 6.2%
- Proportion reaching HbA1c below 5.7% (normal): 27% with tirzepatide vs 6% with semaglutide 1mg
This trial compared tirzepatide to the lower diabetes dose of semaglutide — not the 2.4mg obesity dose. But it remains the best available direct comparison in diabetic patients and shows clear tirzepatide superiority for glycaemic control.
Side Effects: Which Is Better Tolerated?
Both drugs cause similar side effects, primarily gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are most common during dose escalation and typically improve over 4–8 weeks.
Indirect evidence from comparable trials suggests tirzepatide may be marginally better tolerated. In SURMOUNT-1, nausea occurred in 31% of tirzepatide-treated patients. In STEP-1, nausea was reported in 44% of semaglutide patients. This comparison is imperfect (different trials, slightly different dose escalation schedules) but consistently observed across multiple studies.
Both drugs share the same important warnings:
- Thyroid C-cell tumours — Seen in rodent studies; not confirmed in humans but both drugs carry black box warnings. Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2
- Pancreatitis — Rare but serious. Seek immediate care for severe, persistent abdominal pain
- Gallstones — Rapid weight loss increases gallstone risk with both drugs
- Muscle loss — Both drugs cause loss of lean mass alongside fat. Resistance training is essential. See our article on Mounjaro vs Ozempic and muscle loss
Cardiovascular Outcomes: Where Semaglutide Leads
This is the most important area where semaglutide currently has an advantage — and it matters enormously for high-risk patients.
The SELECT trial established that semaglutide 2.4mg reduces major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) by 20% in people with existing cardiovascular disease and overweight/obesity. This was a dedicated cardiovascular outcomes trial with 17,604 participants followed for over 3 years.
Tirzepatide is currently being studied in the SURPASS-CVOT trial for cardiovascular outcomes, but results are not yet available. Based on its superior metabolic effects, many cardiologists expect tirzepatide to show at least equivalent cardiovascular benefit — but the data does not yet exist.
Bottom line: For a patient with established heart disease choosing between these drugs, semaglutide currently has the evidence base. For a patient primarily focused on weight loss or blood sugar without cardiovascular disease, tirzepatide's superior efficacy makes it a strong choice.
Muscle Loss: An Important Difference
Both drugs cause loss of lean mass, but emerging evidence suggests the composition of weight loss differs. Tirzepatide's GIP component activates GIP receptors on fat cells, promoting fat oxidation more selectively. Some early analyses suggest a slightly higher proportion of fat loss and slightly lower proportion of muscle loss with tirzepatide compared to semaglutide — but this requires confirmation in dedicated body composition trials.
Regardless of which drug you use, resistance training (particularly eccentric-focused exercise) and adequate protein intake are essential to preserve muscle during treatment.
Cost and Availability in India
| Factor | Semaglutide (Ozempic) | Tirzepatide (Mounjaro) |
|---|---|---|
| Monthly cost (India approx.) | ₹7,000–12,000 | ₹9,000–15,000 |
| CDSCO approved in India | Yes | Yes (2024) |
| Availability | Good in major cities | Limited; improving |
| Oral form available | Yes (Rybelsus/Novo) | Under development |
Who Should Choose Which Drug?
Choose Semaglutide (Ozempic/Wegovy) if:
- You have established cardiovascular disease (heart attack, stroke history) — SELECT trial evidence applies
- You have chronic kidney disease — FLOW trial shows specific kidney protection
- You prefer an oral option (oral semaglutide pill available)
- Tirzepatide is unavailable in your area
- Cost is a concern — semaglutide is marginally cheaper
Choose Tirzepatide (Mounjaro/Zepbound) if:
- Maximum weight loss is the primary goal
- You have type 2 diabetes and need superior HbA1c reduction
- You experienced inadequate weight loss on semaglutide
- Nausea from semaglutide was intolerable (tirzepatide may be better tolerated)
- No established cardiovascular disease requiring SELECT trial protection specifically
Dr. Ajit Jha's Clinical Perspective
“In practice, I start most patients on semaglutide because of better availability and the stronger cardiovascular evidence base. If someone has tried semaglutide for 6 months with less than 10% weight loss, or has poorly controlled diabetes despite semaglutide, switching to or starting on tirzepatide is a reasonable clinical decision. The efficacy difference in the trials is real — not a statistical artefact. The caveat is that individual response varies enormously; some patients lose 25% on semaglutide while others lose only 5% on tirzepatide. These drugs are powerful tools, but they are not equally effective in every person.”
— Dr. Ajit Jha, MBBS, MD Medicine, IMA Lifetime Member
Frequently Asked Questions
Is Mounjaro stronger than Ozempic?
Yes — in clinical trials, tirzepatide (Mounjaro) produces greater average weight loss (around 20% vs 15%) and superior blood sugar reduction compared to semaglutide (Ozempic) at equivalent trial doses. However, individual responses vary significantly.
Can I switch from semaglutide to tirzepatide?
Yes, switching is possible under medical supervision. Your doctor will typically start tirzepatide at the lowest dose and escalate gradually, regardless of what dose you were on with semaglutide.
Which has fewer side effects — Mounjaro or Ozempic?
Both have similar side effect profiles dominated by nausea, vomiting, and constipation. Cross-trial data suggests tirzepatide may cause slightly less nausea, but direct comparison trials are limited. Individual tolerability varies considerably.
Does tirzepatide work for people who did not lose weight on Ozempic?
Some patients who had limited response to semaglutide do respond to tirzepatide, possibly because of the additional GIP mechanism. This is being studied, but the evidence is not yet definitive — inadequate weight loss on one GLP-1 drug does not guarantee response to another.
Is tirzepatide available in India?
Yes — Mounjaro (tirzepatide) received CDSCO approval in India in 2024. Availability remains limited to major metropolitan areas and select pharmacies. Expect broader availability and potentially lower prices as competition increases.
📖 Related Articles